SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiotechnology -- Ignore unavailable to you. Want to Upgrade?


To: Mike McFarland who wrote (7)5/9/2000 2:55:00 AM
From: Mike McFarland  Read Replies (1) | Respond to of 16
 
Stroke agents
neuro.wustl.edu



To: Mike McFarland who wrote (7)10/1/2000 7:30:07 PM
From: Mike McFarland  Read Replies (1) | Respond to of 16
 
The addition of risperidone would appear to be a useful strategy for augmenting SRI effectiveness in refractory OCD patients.

Int Clin Psychopharmacol 2000 Sep;15(5):297-301
Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.

The Expert Consensus Guideline Series:
Treatment of Obsessive-Compulsive Disorder
psychguides.com